TABLE 2.
Characteristics of the PARIS participants included in the antibody durability data seta
| Antibody durability data set parameter | Total | High baseline titer (800+) | Low baseline titer (<800) |
|---|---|---|---|
| No. (%) of participants | 137 (100.0) | 81 (59.1) | 56 (40.9) |
| Sex (no. [%]) | |||
| Female | 89 (65.0) | 59 (72.8) | 30 (53.6) |
| Male | 48 (35.0) | 22 (27.2) | 26 (46.4) |
| Age (no. [%]) | |||
| <40 | 80 (58.4) | 37 (45.7) | 43 (76.8) |
| 40+ | 57 (41.6) | 44 (54.3) | 13 (23.2) |
| Days enrolled (median, IQR) | 84 (56–168) | 108 (56–192) | 69 (55–112) |
| Days between SOb and enrollment | 154 (91–203) | 147 (63–196) | 182 (133–217) |
| Baseline SARS-CoV-2 antibody titerc | 1:730 (2.67) | 1:1,419 (1.93) | 1:279 (1.52) |
| Seroreversion (no. [%]) | 8 (5.8) | 0 (0.0) | 8 (14.3) |
a
Antibody durability data set (n = 137). Parameter values are presented as number (%) unless indicated otherwise.
b
SO, symptom onset.
c
Geometric mean (standard deviation).